Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION Applying Uniform Pricing Rule to Unprofitable but Essential Drugs Difficult: Kenporen Veep
March 26, 2015
-
BUSINESS 3-Bracket Pricing Rule for Generics Should Be Defended: Sawai Chairman
March 25, 2015
-
BUSINESS Takeda to Collaborate with ImmunoGen for ADC Technology
March 25, 2015
-
BUSINESS AZ Looks to Lead Industry in Immuno-Oncology Arena: Oncology Head
March 24, 2015
-
INTERVIEW Takeda Aims to Return to Growth Track in FY2016, Sales Head Confident in Takecab
March 23, 2015
-
BUSINESS Amgen Astellas Seeks Japan Approval of PCSK9 Inhibitor
March 23, 2015
-
ORGANIZATION FPMAJ Renews Call for Changing NHI Pricing Rules for Unprofitable Drugs with Great Medical Needs
March 20, 2015
-
REGULATORY Chuikyo OKs Quantitative Premium Calculation for Operating Profit Rates
March 19, 2015
-
BUSINESS MSD Revving Up Detailing on Rotavirus, Hepatitis B Vaccines, Eyes Public Immunization Program
March 18, 2015
-
ACADEMIA Researcher Has High Hopes for Immunotherapies as Fourth Pillar of Cancer Treatment
March 17, 2015
-
BUSINESS Takecab Surged to Top Spot in January Anterio Ranking
March 16, 2015
-
REGULATORY Prime Minister Abe Indicates the Need to Promote the Use of Biosimilars
March 16, 2015
-
REGULATORY PMDA Plans to Introduce Full Scale “Patient ADR Reporting System” by FY2018
March 13, 2015
-
BUSINESS Takecab vs PPIs (3): Which Will Come Out on Top? Everything Now in the Hands of Frontline Prescribers
March 13, 2015
-
ORGANIZATION JSGM President Calls for Generic Share Target of 80% by FY2020
March 12, 2015
-
BUSINESS Takecab vs PPIs (2): Takecab to Initially Gain Share for H. pylori Eradication?
March 12, 2015
-
BUSINESS AZ to Tap Rich Pipelines to Grow as Oncology Powerhouse
March 11, 2015
-
BUSINESS Takecab vs PPIs (1): “Rapid, Sustained Efficacy” Pitted against “Patient Satisfaction”, Will Paradigm Shift Occur?
March 11, 2015
-
REGULATORY MHLW to Target 75% Generic Share for Welfare Recipients
March 10, 2015
-
ACADEMIA Interview on SGLT-2 Inhibitor Use (2): Prof. Watada Calls for Caution in Analyzing EPPV Data
March 9, 2015
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…